Oral Contraceptives Petition Seeking Ban On Third-Generation Products Denied By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Public Citizen losses again as the agency says current product labeling for desogestrel-containing oral contraceptives adequately describes the risk of venous thromboembolism; FDA notes the difficulty in comparing the magnitude of risks between combination OCs.
You may also be interested in...
EMA Moves To Reassure Europe Over Combined Contraceptives
EMA says there is currently no cause for concern, amid increasing claims in Europe’s media that combined contraceptives can cause blood clots.
Blood Clot Risk Of Drospirenone Products Remains Open Issue For FDA
Bayer updates labeling for its drospirenone-containing contraceptives to reflect potentially higher risks compared to other birth control pills as FDA seeks ways to get more definitive information.
Contraceptive Compliance Studies May Be Key To Assessing Risk Of Ortho Evra Patch
Some patients in an FDA-funded study had less risk for blood clots than others and finding the reason is a subject for future studies, several members of an advisory panel told FDA Dec. 9. The Reproductive Health Drugs and Drug Safety and Risk Management Committees concluded in a 19-5 vote that the drug’s benefits outweigh its risks.